| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From Merck Research Laboratories (Drs. Reines, Block, Liu, and Lines, M.L. Nessly, B.A. Norman, and C.C. Baranak), Blue Bell, PA; and Washington University School of Medicine (Dr. Morris), St. Louis, MO.
Address correspondence and reprint requests to Dr. C. Lines, Merck Research Laboratories, 10 Sentry Parkway, Blue Bell, PA 19422; e-mail: chris_lines{at}merck.com
Background: Inflammatory mechanisms have been implicated in the pathogenesis of Alzheimer’s disease (AD) and may be mediated via the cyclo-oxygenase–2 enzyme. This study sought to evaluate the effect of rofecoxib, a nonsteroidal anti-inflammatory drug that selectively inhibits cyclo-oxygenase–2, in slowing the progression of dementia in patients with established AD.
Methods: A double-blinded, multicenter trial was conducted in which 692 patients with mild or moderate AD aged 50 years or older were randomly assigned to receive 25 mg rofecoxib or placebo daily for 12 months. The key efficacy measures were mean change from baseline at month 12 on the cognitive subscale of the AD Assessment Scale (ADAS-cog) and score on the Clinician’s Interview Based Impression of Change with caregiver input (CIBIC+).
Results: Four hundred eighty-one patients (70%) completed assessments and remained on treatment at 12 months. No significant differences between treatments were found on the mean change from baseline error score for the ADAS-cog (rofecoxib = 4.84; placebo = 5.44; difference = -0.60) or mean score on the CIBIC+ (rofecoxib = 4.90; placebo = 4.87; difference = 0.03) over 12 months. This result persisted after adjusting for severity of dementia at baseline, presence of the APOE-
4 allele, and donepezil use. Secondary analyses did not reveal any significant differences on any other measures.
Conclusion: The failure of selective cyclo-oxygenase–2 inhibition to slow the progression of AD may indicate either that the disease process is too advanced to modify in patients with established dementia or that cyclo-oxygenase–2 does not play a significant role in the pathogenesis of the disorder.
Received January 6, 2003. Accepted in final form September 16, 2003.
These data were presented at the 8th International Conference on AD and Related Disorders, Stockholm, Sweden, July 20–25, 2002.
This article has been cited by other articles:
|
|
 |
|
  S. Jimenez, D. Baglietto-Vargas, C. Caballero, I. Moreno-Gonzalez, M. Torres, R. Sanchez-Varo, D. Ruano, M. Vizuete, A. Gutierrez, and J. Vitorica Inflammatory Response in the Hippocampus of PS1M146L/APP751SL Mouse Model of Alzheimer's Disease: Age-Dependent Switch in the Microglial Phenotype from Alternative to Classic J. Neurosci., November 5, 2008; 28(45): 11650 - 11661. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 ADAPT Research Group Cognitive Function Over Time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): Results of a Randomized, Controlled Trial of Naproxen and Celecoxib Arch Neurol, July 1, 2008; 65(7): 896 - 905. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. A. Szekely, R. C. Green, J.C.S. Breitner, T. Ostbye, A. S. Beiser, M. M. Corrada, H. H. Dodge, M. Ganguli, C. H. Kawas, L. H. Kuller, et al. No advantage of A{beta}42-lowering NSAIDs for prevention of Alzheimer dementia in six pooled cohort studies Neurology, June 10, 2008; 70(24): 2291 - 2298. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. C. Vlad, D. R. Miller, N. W. Kowall, and D. T. Felson Protective effects of NSAIDs on the development of Alzheimer disease Neurology, May 6, 2008; 70(19): 1672 - 1677. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.-H. Choi, R. Langenbach, and F. Bosetti Genetic deletion or pharmacological inhibition of cyclooxygenase-1 attenuate lipopolysaccharide-induced inflammatory response and brain injury FASEB J, May 1, 2008; 22(5): 1491 - 1501. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. M. Psaty and R. A. Kronmal Reporting Mortality Findings in Trials of Rofecoxib for Alzheimer Disease or Cognitive Impairment: A Case Study Based on Documents From Rofecoxib Litigation JAMA, April 16, 2008; 299(15): 1813 - 1817. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Rogers and M. N. Sabbagh Interactions of stroke, nonsteroidal anti-inflammatory drugs, and APOE status in dementia risk Neurology, January 1, 2008; 70(1): 5 - 6. [Full Text] [PDF]
|
|
|
|
 |
|
 B. P. Imbimbo, E. Del Giudice, D. Colavito, A. D'Arrigo, M. D. Carbonare, G. Villetti, F. Facchinetti, R. Volta, V. Pietrini, M. F. Baroc, et al. 1-(3',4'-Dichloro-2-fluoro[1,1'-biphenyl]-4-yl)-cyclopropanecarboxylic Acid (CHF5074), a Novel {gamma}-Secretase Modulator, Reduces Brain beta-Amyloid Pathology in a Transgenic Mouse Model of Alzheimer's Disease without Causing Peripheral Toxicity J. Pharmacol. Exp. Ther., December 1, 2007; 323(3): 822 - 830. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. M. Hayden, P. P. Zandi, A. S. Khachaturian, C. A. Szekely, M. Fotuhi, M. C. Norton, J. T. Tschanz, C. F. Pieper, C. Corcoran, C. G. Lyketsos, et al. Does NSAID use modify cognitive trajectories in the elderly?: The Cache County Study Neurology, July 17, 2007; 69(3): 275 - 282. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
ADAPT Research Group Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial Neurology, May 22, 2007; 68(21): 1800 - 1808. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Burns and J. O'Brien Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology. J Psychopharmacol, November 1, 2006; 20(6): 732 - 755. [Abstract] [PDF]
|
|
|
|
|
|
J. Zhang, E. L. Ding, and Y. Song Adverse Effects of Cyclooxygenase 2 Inhibitors on Renal and Arrhythmia Events: Meta-analysis of Randomized Trials JAMA, October 4, 2006; 296(13): 1619 - 1632. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Tabet Acetylcholinesterase inhibitors for Alzheimer's disease: anti-inflammatories in acetylcholine clothing! Age Ageing, July 1, 2006; 35(4): 336 - 338. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. R. Ranaivo, J. M. Craft, W. Hu, L. Guo, L. K. Wing, L. J. Van Eldik, and D. M. Watterson Glia as a Therapeutic Target: Selective Suppression of Human Amyloid-beta-Induced Upregulation of Brain Proinflammatory Cytokine Production Attenuates Neurodegeneration J. Neurosci., January 11, 2006; 26(2): 662 - 670. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. P. Townsend and D. Pratico Novel therapeutic opportunities for Alzheimer's disease: focus on nonsteroidal anti-inflammatory drugs FASEB J, October 1, 2005; 19(12): 1592 - 1601. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Sung, H. Yang, K. Uryu, E. B. Lee, L. Zhao, D. Shineman, J. Q. Trojanowski, V. M.-Y. Lee, and D. Pratico Modulation of Nuclear Factor-{kappa}B Activity by Indomethacin Influences A{beta} Levels but Not A{beta} Precursor Protein Metabolism in a Model of Alzheimer's Disease Am. J. Pathol., December 1, 2004; 165(6): 2197 - 2206. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Riggs and R. Holloway Rofecoxib did not slow progression of dementia in patients with established Alzheimer's disease Evid. Based Med., September 1, 2004; 9(5): 148 - 148. [Full Text] [PDF]
|
|
|
|
 |
|
 Minerva BMJ, April 17, 2004; 328(7445): E294 - E294. [Full Text] [PDF]
|
|
|
|
 |
|
 NSAIDs for Alzheimer Disease: Another Negative Study Journal Watch Psychiatry, March 10, 2004; 2004(310): 8 - 8. [Full Text]
|
|
|
|
|
|
Minerva BMJ, February 7, 2004; 328(7435): 356 - 356. [Full Text] [PDF]
|
|
|
|
 |
|
 NSAIDs for Alzheimer Disease: Another Negative Study Journal Watch (General), February 6, 2004; 2004(206): 2 - 2. [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
